<DOC>
	<DOCNO>NCT02264132</DOCNO>
	<brief_summary>The objective study investigate relative BA steady state investigate dose proportionality pharmacokinetic parameter Relative BA steady state : - Pramipexole 0.375 mg ER tablet q.d . versus pramipexole 0.125 mg IR tablet t.i.d . - Pramipexole 1.5 mg ER tablet q.d . versus pramipexole 0.5 mg IR tablet t.i.d . Dose proportionality pharmacokinetic parameter : · Pramipexole ER dosages 0.375 1.5 mg q.d .</brief_summary>
	<brief_title>Increasing Dose Study Pramipexole Two-way Cross-over Comparison ER Tablet Versus IR Tablet Japanese Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pramipexole</mesh_term>
	<criteria>All subject participate study healthy male volunteer Age 20 40 year Body mass index ( BMI ) 17.6 26.4 kg/m2 All volunteer must give write informed consent screen participate study first drug administration Day 1 Visit 2 Any finding medical examination ( include blood pressure , pulse rate , ECG , laboratory test parameter ) clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug administration investigational product Use drug might influence result trial within 7 day start drug administration study study period Participation another trial investigational drug ( within 4 month start drug administration ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day refrain smoke trial site ) Alcohol abuse ( &gt; 40 g/day ) Drug abuse Blood donation ( ≥100 mL within 4 week drug administration trial ) Excessive physical activity 7 day start drug administration end study Any positive result hepatitis B surface antigen ( HBsAg ) , anti hepatitis B core ( HBc ) antibody , anti hepatitis C virus ( HCV ) antibodies human immunodeficiency virus ( HIV ) test The following exclusion criterion special interest study : Hypersensitivity pramipexole dopamine agonist Supine blood pressure screen systolic &lt; 110 mmHg diastolic &lt; 60 mmHg</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>